Othman Al-Sawaf, MD of the University Hospital of Cologne discusses how the results from the multicenter, open-label, randomized, phase 3 CLL14 clinical trial.
As Dr. Al-Sawaf, explains in this video, the trial data showed significant improvement with fixed-duration venetoclax-obinutuzumab (VenG) as compared to chlorambucil-obinutuzumab (ClbG) in patients with untreated chronic lymphocytic leukemia (CLL) and comorbid conditions.
CLL is a rare blood cancer that causes lymphocytes to build up in the bone marrow, and may spread to the lymph nodes and blood. Treatment for asymptomatic CLL patients is often ‘watchful waiting’. However, when symptoms develop, targeted therapies may be necessary which is why follow-up data on potential therapies like VenG are crucial.
For more information on CLL and other rare cancers, visit checkrare.com/diseases/cancers/